Sundaram Hariharan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/83949/publications.pdf

Version: 2024-02-01

45 1,107
papers citations h-

14 32
h-index g-index

45 45 all docs docs citations

45 times ranked 1071 citing authors

#	Article	IF	CITATIONS
1	Long-Term Survival after Kidney Transplantation. New England Journal of Medicine, 2021, 385, 729-743.	27.0	239
2	RECURRENT AND DE NOVO GLOMERULAR DISEASE AFTER RENAL TRANSPLANTATION. Transplantation, 1999, 68, 635-641.	1.0	213
3	Management of the Waiting List for Cadaveric Kidney Transplants. Journal of the American Society of Nephrology: JASN, 2002, 13, 528-535.	6.1	95
4	Prospective Evaluation of Coronavirus Disease 2019 (COVID-19) Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS). Clinical Infectious Diseases, 2022, 75, e630-e644.	5.8	65
5	Kidney allograft surveillance biopsy practices across US transplant centers: A UNOS survey. Clinical Transplantation, 2017, 31, e12945.	1.6	53
6	Short-term adverse effects of early subclinical allograft inflammation in kidney transplant recipients with a rapid steroid withdrawal protocol. American Journal of Transplantation, 2018, 18, 1710-1717.	4.7	50
7	Post-transplant donor specific antibody is associated with poor kidney transplant outcomes only when combined with both T-cell–mediated rejection and non-adherence. Kidney International, 2019, 96, 202-213.	5.2	48
8	Subclinical Rejection in Renal Transplantation. Transplantation, 2016, 100, 1610-1618.	1.0	44
9	Early subclinical tubulitis and interstitial inflammation in kidney transplantation have adverse clinical implications. Kidney International, 2020, 98, 436-447.	5.2	31
10	Transitional B cell cytokines predict renal allograft outcomes. Science Translational Medicine, 2021, 13, .	12.4	30
11	Anti-CD20 Blocker Rituximab in Kidney Transplantation. Transplantation, 2018, 102, 44-58.	1.0	26
12	Economic analysis of screening for subclinical rejection in kidney transplantation using protocol biopsies and noninvasive biomarkers. American Journal of Transplantation, 2021, 21, 186-197.	4.7	24
13	The Impact of Early Clinical and Subclinical T Cell–mediated Rejection After Kidney Transplantation. Transplantation, 2019, 103, 1457-1467.	1.0	23
14	High Calcineurin Inhibitor Intrapatient Variability Is Associated With Renal Allograft Inflammation, Chronicity, and Graft Loss. Transplantation Direct, 2019, 5, e424.	1.6	18
15	Kidney Transplant Outcomes After Primary, Repeat and Kidney After Nonrenal Solid Organ Transplantation. Transplantation Direct, 2016, 2, e75.	1.6	16
16	Cerebrovascular disease: Neuroimaging of cerebral small vessel disease. Progress in Molecular Biology and Translational Science, 2019, 165, 225-255.	1.7	16
17	Early allograft inflammation and scarring associate with graft dysfunction and poor outcomes in renal transplant recipients with delayed graft function: a prospective single center cohort study. Transplant International, 2018, 31, 1369-1379.	1.6	15
18	Donor acute kidney injury and its effect on 1â€year postâ€transplant kidney allograft fibrosis. Clinical Transplantation, 2020, 34, e13770.	1.6	11

#	Article	IF	CITATIONS
19	Kidney allograft rejection: Diagnosis and treatment practices in USA―A UNOS survey. Clinical Transplantation, 2021, 35, e14225.	1.6	11
20	Trends and impact on cold ischemia time and clinical outcomes using virtual crossmatch for deceased donor kidney transplantation in the United States. Kidney International, 2021, 100, 660-671.	5.2	10
21	Cytomegalovirus infection in highâ€risk kidney transplant recipients receiving thymoglobulin induction—a singleâ€center experience. Clinical Transplantation, 2016, 30, 1159-1164.	1.6	9
22	Outcomes of Adult Intestinal Transplant Recipients Requiring Dialysis and Renal Transplantation. Transplantation Direct, 2018, 4, e377.	1.6	7
23	KDOQI US Commentary on the 2020 KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. American Journal of Kidney Diseases, 2021, 77, 833-856.	1.9	7
24	Rituximab induction for prevention of HLA-antibody rebound. Nature Reviews Nephrology, 2014, 10, 682-683.	9.6	6
25	The Combined Roles of Race/Ethnicity and Substance Use in Predicting Likelihood of Kidney Transplantation. Transplantation, 2022, 106, e219-e233.	1.0	6
26	Screening coronary angiography in patients with longâ€standing diabetes mellitus undergoing kidney transplant evaluation. Clinical Transplantation, 2019, 33, e13501.	1.6	4
27	Tests for the noninvasive diagnosis of kidney transplant rejection should be evaluated by kidney transplant programs. American Journal of Transplantation, 2021, 21, 3811.	4.7	4
28	Incentivization of Living Donation: Is It Time to Cross the Bridge?. American Journal of Kidney Diseases, 2014, 64, 484-485.	1.9	3
29	Xenotransplantation. Organogenesis, 2018, 14, 159-162.	1.2	3
30	Bimonthly viral monitoring for lateâ€onset cytomegalovirus infection in kidney transplant recipients. Clinical Transplantation, 2021, 35, e14259.	1.6	3
31	Epidemiology of endâ€stage renal failure among twins and diagnosis, management, and current outcomes of kidney transplantation between identical twins. American Journal of Transplantation, 2020, 20, 761-768.	4.7	2
32	Donor-derived Cell-free DNA for the Diagnosis of Kidney Transplant Rejection: An Attractive Test With Ambiguous Answers!. Transplantation, 2021, 105, 1171-1172.	1.0	2
33	Moderately Macrosteatotic Livers Have Acceptable Long-Term Outcomes but Higher Risk of Immediate Mortality. Transplantation Proceedings, 2021, 53, 1682-1689.	0.6	2
34	Rabbit antithymocyte globulin dose and early subclinical and clinical rejections in kidney transplantation. Clinical Transplantation, 2022, 36, e14582.	1.6	2
35	Preoperative blood pressure and risk of delayed graft function in deceased donor kidney transplantation. Clinical Transplantation, 0, , .	1.6	2
36	A Markov Analysis of Screening for Late-Onset Cytomegalovirus Disease in Cytomegalovirus High-Risk Kidney Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 290-298.	4.5	1

#	Article	IF	CITATIONS
37	Octreotide Delaying the Progression of Recurrent IgA Nephropathy After Kidney Transplantation. Transplantation Direct, 2020, 6, e518.	1.6	1
38	Evaluation of Renal Anionic Secretion Following Living-donor and Deceased-donor Renal Transplantation: A Clinical Pharmacokinetic Study of Cefoxitin Microdosing. Transplantation Direct, 2020, 6, e561.	1.6	1
39	Author response to comments on economic analysis of subclinical rejection screening in kidney transplantation. American Journal of Transplantation, 2021, 21, 1348-1349.	4.7	1
40	Donation after circulatory death is associated with increased fibrosis on 1â€year postâ€transplant kidney allograft surveillance biopsy. Clinical Transplantation, 2021, 35, e14399.	1.6	1
41	From infection to immunity - Impact of COVID-19 across nine hemodialysis centres in Mumbai. Indian Journal of Nephrology, 2021, 31, 544.	0.5	1
42	Impact of Size Matching Based on Donor-Recipient Height on Kidney Transplant Outcomes. Transplant International, 2022, 35, 10253.	1.6	1
43	Live Donor Kidney Transplantation. Transplantation, 2018, 102, 1211-1212.	1.0	0
44	The authors reply. Kidney International, 2020, 98, 516.	5.2	0
45	Kidney Transplant Survival: Transforming Early Post-Transplant Opportunities to Long-Term Success. Clinical Transplants, 2015, 31, 227-237.	0.2	O